Cannabinol (CBN) is a rare cannabinoid showing unique, potentially medically important properties for diseases with high unmet medical needs. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. Is cannabinol safe? Is cannabinol psychoactive?
Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thus earning it an orphan-disease status. The disease has no definitive cure and all current treatments are directed towards symptom relief.
Glaucoma is a group of eye diseases which results in damage to the optic nerve due to high intraocular pressure (IOP) of the eye from fluid build-up. Glaucoma is the second leading cause of vision loss.
What are the GMP requirements for pharmaceuticals, medicinal cannabis, cosmetics, dietary supplements, and food and beverage products?
Good Manufacturing Practices, or GMP for short, are minimum manufacturing standards required for different industries. Learn about how GMP requirements differ based on product type.
The use of cannabis to treat glaucoma has extensive anecdotal evidence and supporting clinical data in the literature. It has been definitively demonstrated in articles that smoking cannabis lowers intraocular pressure (IOP) in both normal individuals and in those with glaucoma. Although the role of cannabinoids in treating glaucoma is thought to be very well understood according to the 2004 publication from Tomida, et al., entitled “Cannabinoids and glaucoma”, no such products are currently approved for this disease.
Cannabinoids fall into three general types: (1) phytocannabinoids, such as those that can be isolated from the Cannabis plant; (2) endogenous cannabinoids (“endocannabinoids”), which are produced naturally in the bodies of humans and animals; and (3) synthetic cannabinoids, which are produced in the laboratory and may have structural deviations from the naturally occurring drugs.